Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 3, 2000, Pages 589-594

  Stamilio, David M ^a,b   Sehdev, Harish M ^c   Morgan, Mark A ^a   Propert, Kathleen ^b   Macones, George A ^a,b  

^a Department of Obstetrics and Gynecology ^*  (United States)

^b Center for Clinical Epidemiology and Biostatistics   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biochemical markers; Clinical prediction rule; Preeclampsia

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; PREDICTION; PREECLAMPSIA; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0034070780     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.103890     Document Type: Article

References (25)

1. 1. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163:1049-54.
2. 2. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994;309:1395-400.
3. 3. Lopez-Llera MM. Complicated eclampsia: fifteen years' experience in a referral medical center. Am J Obstet Gynecol 1982;142:28-35.
4. 4. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial [published erratum appears in Lancet 1995;346:258]. Lancet 1995;345:1455-63.
5. 5. Sibai BM, Taslimi M, Abdella TN, Brooks TF, Spinnato JA, Anderson GD. Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester. Am J Obstet Gynecol 1985;152:32-7.
6. 6. Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, Ryan GM, Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986;155:501-9.
7. 7. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPFP) Study Group. Am J Obstet Gynecol 1997;177:1003-10.
8. 8. Dekker GA, Makovitz JW, Wallenburg HC. Comparison of prediction of pregnancy-induced hypertensive disease by angiotensin II sensitivity and supine pressor test. Br J Obstet Gynaecol 1990;97:817-22.
9. 9. Kuntz WD. Supine pressor (roll-over) test: an evaluation. Am J Obstet Gynecot 1980;137:764-8.
10. 10. Caritis SN. Predictors of preeclampsia in high risk women. NICHD-MFMU Network. Am J Obstet Gynecol 1998;178 Suppl:S104.
11. 11. Muller F, Savey L, Le Fiblec B, Bussieres L, Ndayizamba G, Colau JC, et al. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Am J Obstet Gynecol 1996;175:37-40.
12. 12. Lee IS, Chung DY, Cole LA, Copel JA, Isozaki T, Hsu CD. Elevated serum nicked and urinary beta-core fragment hCG in preeclamptic pregnancies. Obstet Gynecol 1997;90:889-92.
13. 13. Ashour AM, Lieberman ES, Wilkens-Huag L, Repke JT. The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol 1997;176:438-42.
14. 14. Shipp TD, Wilkins-Haug L. The association of early-onset fetal growth restriction, elevated maternal serum alpha-fetoprotein, and the development of severe preeclampsia. Prenat Diagn 1997;17:305-9.
15. 15. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 1996;88:816-22.
16. 16. Wenstrom KD, Owen J, Davis RO, Brumfield CG. Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein. Obstet Gynecol 1996;87:213-6.
17. 17. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Hosmer DW, Lemeshow S, editors. Applied logistic regression. New York: Wiley-Interscience; 1989. p. 135-73.
18. 18. Isouard G. Measurement of serum levels of oestriol and human placental lactogen in the management of preeclamptic pregnancies. Med J Aust 1979;2:401-4.
19. 19. Isouard G. Value of total serum oestriol and human placental lactogen in the assessment of fetal-placental function. Aust N Z J Obstet Gynaecol 1979;19:69-76.
20. 20. Cincotta RB, Brennecke SP. Family history of preeclampsia as a predictor for preeclampsia in primigravidas. Int J Gynaecol Obstet 1998;60:23-7.
21. 21. Sutherland A, Cooper DW, Howie PW, Liston WA, MacGillivray I. The incidence of severe preeclampsia amongst mothers and mothers-in-law of preeclamptics and controls. Br J Obstet Gynaecol 1981;88:785-91.
22. 22. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408-12.
23. 23. Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of preeclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1997;104:674-81.
24. 24. Millar JG, Campbell SK, Albano JD, Higgins BR, Clark AD. Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample. Br J Obstet Gynaecol 1996;103:421-6.
25. 25. Kimya Y, Akdi C, Cengiz C, Ozan H, Tatlikazan S, Uncu G, et al. Plasma interleukin-1alpha, interleukin-1beta and interleukin-1 receptor antagonist levels in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73:17-21.